Tranexamic Acid: Oral 250mg BID Produces 65% Good-to-Excellent Response in Melasma
Tranexamic Acid (TXA) has positioned itself as a first-line approach option for melasma. Oral 250-500 mg twice daily produces good-to-excellent response in about 65% of patients, controlling pigmentation without hydroquinone’s rebound pigmentation risk.
Why Plasmin Inhibition Works for Melasma
TXA is originally an antifibrinolytic, inhibiting plasmin in clotting. The melasma discovery came from realizing UV exposure activates plasmin in keratinocytes, which then stimulates melanin synthesis in melanocytes.
When TXA inhibits plasmin, melanocyte-keratinocyte interaction weakens, and melanin production decreases. This operates on a different layer than hydroquinone (direct tyrosinase inhibition) or azelaic acid (tyrosinase inhibition).
Three Delivery Routes
Oral TXA:
- Dose: 250-500 mg twice daily
- Systemic action for broad melasma
- 65% good-to-excellent response
- No thrombotic events in 28-month use
Topical TXA:
- Concentration: 3-5% cream
- Twice daily
- No systemic side effects, local management
Intradermal Injection:
- 0.5-1 ml at 4-week intervals
- Dermatology procedure
- Combined with oral or topical
Systematic Review Meta-Analysis
A 2024 meta-analysis showed oral TXA produces statistically significant pigmentation index improvement vs. placebo and other treatments, with QoL score improvements. Oral+topical combinations outperformed single routes.
Long-Term Safety: 28-Month Use
Melasma is chronic, making long-term safety critical. A 2024 JAAD International retrospective case series reported no thromboembolic events in patients using oral TXA for up to 28 months. Main side effects:
- Mild GI discomfort (most common)
- Menstrual irregularities
- Headache
- Fatigue
All mild with high treatment continuation.
Contraindications and Caution Groups
TXA is contraindicated in thromboembolism risk groups:
- DVT or pulmonary embolism history
- Hereditary thrombophilia (Factor V Leiden)
- Oral contraceptive users (relative caution)
- Smoking + age 35+
- Cardiovascular disease
These groups use topical TXA only or switch to other options (azelaic acid, hydroquinone).
FDA Status
TXA is not FDA-approved for melasma. Approved only for heavy menstrual bleeding. Melasma is “off-label” use. In many markets, dermatologists prescribe it, but clinician supervision is recommended.
Compared to Azelaic Acid and Hydroquinone
| Ingredient | Mechanism | Pregnancy Safety | Side Effects |
|---|---|---|---|
| TXA (oral) | Plasmin inhibition | Contraindicated | Thrombosis risk, GI |
| TXA (topical) | Plasmin inhibition | Relatively safe | Minimal |
| Azelaic acid | Tyrosinase inhibition | Safe (B) | Mild irritation |
| Hydroquinone | Direct tyrosinase inhibition | Contraindicated | Rebound pigmentation |
2026 melasma standard treatment isn’t a single ingredient but multi-pathway combinations. Morning azelaic + vitamin C + SPF, evening topical TXA or hydroquinone, add oral TXA if needed, with sun protection as the foundation of all strategies.
Broader Context
Melasma prevalence runs 25-40% in Asian women, surging after age 40. UV, hormones, pregnancy, and oral contraceptives are main triggers. The three-layer strategy of oral TXA + sun protection + topical brightening is widely used in Asian dermatology practice, requiring thrombosis risk assessment and clinician consultation.